Evaluation of immunostimulatory effects of foods

Evaluation of immunostimulatory effects of foods - Evaluation of immunostimulatory effects of foods

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033953

Enrollment

Registered

2018-09-18

Start date

2018-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Oral intake of the test food (112 mL) once a day for 3 weeks Oral intake of the placebo (112mL) once a day for 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subjects who have given written informed consent 2) Subjects aged 30 to 65 years old 3) Subjects whose body mass index (BMI) is from 18.5 kg/m2 to 24.9 kg/m2 4) Subjects who have not received a vaccination within the past half year and are not planning to get a vaccination during the study.

Exclusion criteria

Exclusion criteria: 1) Subjects who have immune related diseases or its medical histories 2) Cancer patients 3) Subjects who have psychological diseases 4) Subjects who have infectious diseases 5) Subjects who have asthma, food allergy, atopic dermatitis or their medical histories 6) Subjects who intake anti-inflammatory drugs, immunosuppressants, antibiotics, anti-allergic drugs 7) Subjects who are pregnant, or wish to be pregnant during the study 8) Lactating women 9) Subjects who are intolerant to lactose 10) Smokers 11) Subjects who have a habit to take alcohol(expressed in amount of alcohol: over 60 g/day) 12) Subjects who have a habit to take fermented milks, foods for specified health use, or dietary supplements containing probiotics more than once a day 13) Subjects who have a habit to take pharmaceuticals, health foods or dietary supplements containing ingredients can affect immune system more than 3 times a week within past 2 weeks 14) Subjects who have participated in other clinical trials within a month or plan to participate other clinical trials during this study period 15) Subjects who are judged not suitable to participate in this trial by principal investigator or subinvestigators

Design outcomes

Primary

Measure	Time frame
CD69 expression on T cells	—

Secondary

Measure	Time frame
Expressions of activation markers on T cells Expressions of senescence markers on T cells Lymphocyte blastoid transformation	—

Countries

Japan

Contacts

Public ContactSeiya Makino

Meiji Co., Ltd. Food Microbiology Research Laboratories, R&D Division

seiya.makino@meiji.com042-632-5842

Outcome results